Listed

BridgeBio Pharma, Inc.

BBIOQ3 FY2026Period ended Sep 30, 2026

Fiscal period
Q3 FY2026
Period end
2026-09-30
Report due by
2026-11-06from the company's last four reports
Margin metric
Operating margin
Status
Scored
Scored against
The 10-Q for the quarter, figures as first reported
Locks
Locked Oct 29, 2026, 16:03 ET

Locked

Forecasts locked Oct 29, 2026, 16:03 ET, when EDGAR accepted BridgeBio Pharma, Inc.'s 8-K (2.02 Results of operations), accession 0001743881-26-000033. Anything saved after that second does not count.

Reported

Actuals as first reported in the 10-Q, accession 0001743881-26-000034, scored Oct 29, 2026. Faint ticks are every counted forecast; the shaded band is the tolerance.

Revenue, reported$353.2m
Diluted EPS, reported−$0.42
Operating margin, reported−3.3%

Forecast against actual

Members with a public profile.

No public forecasts on this target.

The formula

Each metric is scored on its own. A metric that scores above 0 is a hit. League rules

score = 100 × max(0, 1 − |forecast − actual| / tolerance)
  • Revenuetolerance 10% of the actual: $35.3m
  • Diluted EPStolerance 20% of the actual, at least $0.05: $0.08
  • Operating margintolerance 5 percentage points